BlackRock
ALGS icon

BlackRock’s Aligos Therapeutics ALGS Stock Holding History

BlackRock’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$175K Buy
30,292
+17,252
+132% +$107K ﹤0.01% 4851
2026
Q1 		$96.9K Hold
13,040
– – ﹤0.01% 4968
2025
Q4 		$122K Hold
13,040
– – ﹤0.01% 4852
2025
Q3 		$128K Hold
13,040
– – ﹤0.01% 4780
2025
Q2 		$94K Hold
13,040
– – ﹤0.01% 4855
2025
Q1 		$108K Sell
13,040
-681
-5% -$14.9K ﹤0.01% 4751
2024
Q4 		$547K Buy
13,721
+4,654
+51% +$89.9K ﹤0.01% 4391
2024
Q3 		$78.5K Sell
9,067
-29
-0.3% -$361 ﹤0.01% 4720
2024
Q2 		$79.6K Sell
9,096
-3,054
-25% -$53.7K ﹤0.01% 4753
2024
Q1 		$298K Buy
12,150
+304
+3% +$6.05K ﹤0.01% 4504
2023
Q4 		$197K Sell
11,846
-32
-0.3% -$550 ﹤0.01% 4642
2023
Q3 		$222K Sell
11,878
-141
-1% -$3.13K ﹤0.01% 4649
2023
Q2 		$292K Sell
12,019
-285
-2% -$7.64K ﹤0.01% 4632
2023
Q1 		$269K Buy
12,304
+6
+0% +$229 ﹤0.01% 4700
2022
Q4 		$293K Sell
12,298
-8,404
-41% -$212K ﹤0.01% 4746
2022
Q3 		$569K Sell
20,702
-320
-2% -$10.6K ﹤0.01% 4682
2022
Q2 		$636K Sell
21,022
-43,019
-67% -$1.46M ﹤0.01% 4694
2022
Q1 		$3.44M Buy
64,041
+109
+0.2% +$8.73K ﹤0.01% 4146
2021
Q4 		$19M Buy
63,932
+14,350
+29% +$5.23M ﹤0.01% 3306
2021
Q3 		$19.2M Buy
49,582
+6,220
+14% +$2.46M ﹤0.01% 3305
2021
Q2 		$22.1M Buy
43,362
+15,527
+56% +$9.9M ﹤0.01% 3236
2021
Q1 		$15.8M Buy
27,835
+1,251
+5% +$833K ﹤0.01% 3308
2020
Q4 		$18.4M Buy
+26,584
New +$12.9M ﹤0.01% 3053

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlackRock's ALGS Position: Q2 2026 in Review

BlackRock increased its Aligos Therapeutics (ALGS) stake by 132% in Q2 2026, buying an estimated $107K and bringing the position to 30,292 shares worth $175K. The position accounts for ﹤0.01% of the portfolio, ranked #4851.

BlackRock first reported a position in ALGS in Q4 2020 and has held it in 23 quarters since. The position peaked at $22.1M in Q2 2021. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

  • BlackRock held 30,292 shares of Aligos Therapeutics worth $175K as of Q2 2026.
  • BlackRock bought 17,252 Aligos Therapeutics shares in Q2 2026, an estimated $107K.
  • Aligos Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4851 holding.
  • BlackRock first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • BlackRock's Aligos Therapeutics position peaked at $22.1M in Q2 2021.
  • 31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.